







# Shared HCV Transmission Networks among HIV-1 Positive and Negative Men Having Sex with Men by Ultra-Deep Sequencing in Paris

**Abstract number: THAB0203** 

**Thuy NGUYEN**, Constance DELAUGERRE, Marc-Antoine VALANTIN, Corinne AMIEL, Emmanuelle NETZER, Thomas L'YAVANC, Michele OHAYON, Pierre-Marie GIRARD, Nesrine DAY, Georges KREPLAK, Gilles PIALOUX, Vincent CALVEZ, Jean-Michel MOLINA, Anne-Geneviève MARCELIN, and Eve TODESCO







### Introduction

### ■ HCV incidence in men having sex with men (MSM)

- Outbreaks of Acute hepatitis C in developed countries [1-3]
- In HIV+ MSM
  - ➤ ↑ HCV incidence from 2012 to 2016 in France (4.3/1000 PY to 11.1/1000 PY) [4]
  - High HCV reinfection rate in Paris (218/1000 PY) [5]
  - Pooled HCV incidence in HIV+ MSM was 7.8/1000 PY [6]
- In HIV- MSM
  - Pooled HCV incidence was 0.4/1000 PY [6] but can reach 14/1000 PY in MSM included in the ANRS IPERGAY Pre-Exposure Prophylaxis (PrEP) trial [7]

#### HCV transmission networks

- Large European HCV transmission networks in HIV+ MSM (78% of sequences formed 11 clusters of 4-37 individuals) [2]
- Spread of HCV from HIV+ to HIV- MSM [8,9]

# Introduction

### Transmission chains

- Viral sequences more genetically similar to each other than expected by chance, demonstrated by a tight cluster on phylogenetic trees
- Satisfying branch support and genetic distance threshold requirements<sup>[1]</sup>
- Sequencing of polymerase (NS5B)<sup>[2]</sup> or hypervariable region (HVR)<sup>[3]</sup>

### Available techniques

- Sanger sequencing: gold standard for clinical monitoring of patients but unable for a deep characterization of intra-host genetic diversity
- Ultra-deep sequencing (UDS): allows an extensive analysis of viral population (minority variants)

# **Objectives**

■To identify and deeply characterize HCV transmission chains in HIV+ and HIV- MSM in Paris

■To detect closely related HCV transmission events among them (directness inference)

# **Methods**

□ Sanger sequencing and UDS on polymerase fragment (NS5B, 388 bp)

Approximative maximum likelihood with GTR model (FastTree v 2.1)

-> Phylogenetic tree construction

□ Transmission chain determination at different thresholds of maximum genetic distance (MGD) with bootstrap value > 80% (ClusterPicker v 1.2.3)

Sanger: 3% of MGD

UDS: 3% and 4.5% of MGD

## **Patients**

- □ 68 patients with acute hepatitis C including
  - 55 (50 HIV+ and 5 HIV-) patients followed at the Pitié-Salpêtrière, Saint-Antoine, and Tenon hospitals, Paris, France or by their referring physicians
  - 13 HIV- patients from ANRS IPERGAY trial (MSM at high risk for HIV acquisition and under PrEP) [1,2]

### **Patients' characteristics**

Characteristics	Total (n=68)	HIV+ patients (n=50)	HIV- patients (n=18)
Age (years), median (IQR)	38.5 (30.5-46.0)	42.5 (34.5-46.0)	32.0 (27.5-35.8)
Men having sex with men, n (%)	58 (85.3)	43 (86.0)	15 (83.3)
Unknown sexual orientation, n (%)	10 (14.7)	7 (14.0)	3 (16.7)
HCV viral load, log copies/ml, median (IQR)	5.9 (5.3-6.7)	5.9 (5.3-6.9)	5.5 (5.3-5.6)
HCV genotype			
➤ Genotype 1a, n (%)	32 (47.1)	24 (48.0)	8 (44.4)
Genotype 4d, n (%)	28 (41.2)	20 (40.0)	8 (44.4)
Genotype 3a, n (%)	6 (8.8)	5 (10.0)	1 (5.6)
➤ Genotype 2k, n (%)	2 (2.9)	1 (2.0)	1 (5.6)
ALAT (IU/L), median (IQR)	320.0 (146.5-535.5)	315.0 (144.8-480.8)	467.0 (234.0-647.0)
HIV co-infection (%)	50 (73.5)	50 (100.0)	/
HCV reinfection (%)	15 (22.1)	14 (28.0)	1 (5.6)

# More HCV transmission chains detected by UDS but fewer subjects identified in each chain

### Identification of HCV transmission chains by Sanger and UDS

	Sanger 3.0% of MGD	UDS 3.0% of MGD	UDS 4.5% of MGD
Number of subjects included in a transmission chain, n (%)	38 (55.9)	38 (55.9)	43 (63.2)
Number of transmission chains	10	17	18
Median of subjects (min-max)	3 (2-6)	2 (2-5)	2 (2-6)

MGD: Maximum Genetic Distance

- Subjects in some transmission chains found by UDS were grouped into larger chains by Sanger.
- 3 and 4 hidden transmission chains were detected only by UDS at 3% and at 4.5 % of MGD, respectively.


# Shared HCV transmission networks among HIV positive and negative subjects

### **Transmission chains including HIV+ and HIV- subjects**

	Sanger 3.0 % of MGD	UDS 3.0 % of MGD	UDS 4.5% of MGD
HCV transmission chains including HIV+ and HIV- subjects, n/number of chains	8/10	9/17	10/18
Number of HIV- clustering with HIV+ subjects, n/total number of HIV- subjects	9/18	9/18	10/18

MGD: Maximum Genetic Distance

➤ High HCV clustering rate among HIV+ and HIV- MSM communities detected by both techniques



### Closely related HCV transmission events (MGD < 0.5 %)




Figure: Phylogenetic tree constructed from UDS viral sequences of 2 individuals (pink circle and brown triangle)

Red clades: sequences with MGD < 0.5%

between 2 individuals.

Blue clades: identical sequences (MGD =

0%) between 2 individuals

# **Discussion**

### **Both techniques**

- High clustering rate of HCV among HIV+ and HIV- MSM communities
  - At least 50% of HIV- subjects enrolled in this study clustering with HIV+ ones

### **UDS**

- □ Improved discrimination of HCV transmission chains (through transmission of multiple viral strains/minority variants)
  - Detection of closely related HCV transmission events and of hidden transmission chains

- □ Identified fewer subjects in each chain *vs* Sanger because of deeper viral population characterization by UDS (↑ viral diversity)
  - Difficult to determine a cut-off of MGD
  - For large-scale prevention and rapid intervention purposes, UDS is not more useful than Sanger

# **Discussion**

- Closely related transmission events
  - Suggesting direct transmissions without totally excluding intermediary links

- Shared HCV transmission networks among HIV+ and HIV- MSM in Paris
  - Need of better screening and surveillance of HCV infection in the subgroup of MSM with high-risk behaviors whatever the HIV status

- ☐ Further investigation of the high-throughput sequencing data
  - With European MSM sequences of HCV









### **Acknowledgement**

- ☐ This study was funded by Agence Nationale de Recherche sur le SIDA et les hépatites virales (ANRS).
- We thank the Virology research team, Pitié-Salpêtrière and Saint-Antoine hospitals, Institut Pierre Louis d'Epidémiologie et de Santé publique, INSERM U1136 (Prs. CALVEZ, MARCELIN, MORAND JOUBERT, Drs WIRDEN, SOULIE, LAMBERT-NICLOT, FOFANA, JARY, ABDI and other colleagues MALET, SAYON, DESIRE).
- We thank
  - the INSERM SC10 and the Trial Scientific Committee for IPERGAY trial.
- We thank
  - all the patients who agreed to participate in the study.
  - all the participant doctors who followed the patients, in particular Drs ROUDIERE, LIOTIER, GOSSET, CARDON, GRIVOIS, ISRAEL, KIRSTETTER, LAYLAVOIX, BOTTERO, WORMSER and Pr. KATLAMA.
  - > all the participant virologists, Drs AMIEL, ELAERTS and SCHNEIDER.



